APOA4 and metabolic dysfunction-associated steatotic liver disease: Further studies showed that APOA4 inhibited hepatic steatosis by down-regulating SREBF1-mediated lipogenesis and improved hepatic insulin sensitivity through IRS-PI3K-Akt signaling, thus ameliorating NAFLD [88].